That's a really important question, and unfortunately it's one that requires going straight to the source — Kaiser's own authorization or prior approval team — since insurance coverage decisions vary by plan, region, and individual health profile.
What is known is that Filspari (sparsentan) has received FDA approval for Show Full Answer
That's a really important question, and unfortunately it's one that requires going straight to the source — Kaiser's own authorization or prior approval team — since insurance coverage decisions vary by plan, region, and individual health profile.
What is known is that Filspari (sparsentan) has received FDA approval for adults with primary IgAN who are at risk of disease progression. It works in two ways:
- Blocking angiotensin to help lower blood pressure and reduce kidney stress
- Blocking endothelin, another substance that narrows blood vessels and adds pressure on the kidneys
Together, these actions may help slow kidney damage in IgAN. To find out if Kaiser will authorize it specifically for advanced kidney disease, a few steps worth considering:
1. Ask the nephrologist to submit a prior authorization request with supporting documentation about disease progression
2. Request a peer-to-peer review between the doctor and Kaiser's medical reviewer if initially denied
3. Appeal a denial if necessary — doctors can often provide clinical evidence supporting the need for this specific medication
Having a nephrologist advocate directly can make a big difference in these situations.
August 12
Continue with Facebook
Continue with Email
Join
Your Privacy Choices
